Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Journal of Oncology Practice|February 16, 2018
Drug-Addicted Oncology Practice: The Drug TestNeil M Barth, Beau DoneganCancer Biotherapy & Radiopharmaceuticals|July 19, 2012
Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma?Robert O Dillman, Neil M Barth, Louis A VanderMolen, et al.American Journal of Clinical Oncology|June 1, 2005
High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplantsRobert O Dillman, Neil M Barth, Louis A VanderMolen, et al.American Journal of Clinical Oncology|April 26, 2003
Does continuous-infusion interleukin-2 increase survival in metastatic melanoma?Robert O Dillman, Audrey A O'Connor, Linda Simpson, et al.Cancer Biotherapy & Radiopharmaceuticals|June 30, 2011
Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer?Robert O Dillman, Neil M Barth, Louis A VanderMolen, et al.Cancer Biotherapy & Radiopharmaceuticals|March 28, 2002
Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survivalRobert O Dillman, Linda D Beutel, Neil M Barth, et al.Cancer Biotherapy & Radiopharmaceuticals|July 27, 2007
Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanomaRobert O Dillman, Carol DePriest, Cristina DeLeon, et al.Cancer Biotherapy & Radiopharmaceuticals|June 18, 2015
Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of TreatmentRobert O Dillman, Edward F McClay, Neil M Barth, et al.Cancer Biotherapy & Radiopharmaceuticals|June 23, 2009
Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final reportRobert O Dillman, Senthamil R Selvan, Patric M Schiltz, et al.BMC Genomics|May 17, 2018
Identification of usual interstitial pneumonia pattern using RNA-Seq and machine learning: challenges and solutionsYoonha Choi, Tiffany Ting Liu, Daniel G Pankratz, et al.Pageof 2